Musk employees eager to cash out as Neuralink's value soars

Neuralink Employees Prepare to Sell Stock Amid Valuation Surge Post-Human Trial

Staff at Elon Musk's brain implant company, Neuralink, are planning to sell their stock, aiming to capitalize on the company's increased valuation following its first human trial. Stock compensation at startups like Neuralink can be highly lucrative, though these shares are not publicly traded. Employees wishing to sell have to navigate a complex network of niche private market exchanges.

Sources indicate that some Neuralink employees and investors are gearing up for a tender offer from the company to buy back shares from those looking to sell, possibly as early as next month. This move comes after Neuralink's valuation spiked dramatically post-human trial. Secondary market trades have shown a significant rise in value, with some transactions hinting at an $8 billion valuation, which is more than double last year's figures.

Upcoming Tender Offer

The tender offer, if confirmed, follows a similar strategy implemented by the company last fall. Neuralink offered to buy shares from employees at about $19 per share, while secondary market trades valued them closer to $35. It is a common practice for startups to offer share buybacks at a discount relative to secondary market values to create scarcity and drive up demand.

Elon Musk's tactics to maintain an exclusive investor base have been observed not just with Neuralink but also with his other ventures, including SpaceX and xAI. This exclusivity has often resulted in shares being highly sought after, even with limited information available about these companies once investments are made.

Private Market Premiums

Multiple buyers on private exchanges have been paying premiums varying between 84% and 137% based on Neuralink's latest private fundraising valuation from last November. This valuation stood at $3.5 billion, but the demand has pushed recent offers much higher, with some proposing as much as $50 per share.

SpaceX, another Musk venture, also experiences similar premium trades in the secondary market. A recent transaction valued SpaceX at $232 billion, substantially higher than its $180 billion valuation from a private fundraising event in April.

Regulatory and Strategic Considerations

Neuralink discourages its employees from trading shares on the secondary market, favoring controlled tender offers instead. One primary reason is federal regulation, which limits private companies to 2,000 direct shareholders. Limitless secondary trading can push a company towards this cap. Additionally, controlled tender offers allow companies to channel stock sales to favored investors at prices they determine.

Restrictions placed on trading mean that Hiive, a secondary trading platform, can only facilitate matchmaking for Neuralink shares. Payment and share transfer arrangements are left to the parties involved.

Conclusion

The surge in Neuralink’s valuation post-human trial presents a lucrative opportunity for employees holding stock. As the company moves towards additional trials and potentially another tender offer, the value of shares is expected to remain high, attracting significant attention from buyers and investors alike. However, regulatory restrictions and strategic company policies will continue to shape the trading landscape for Neuralink shares.